Achieve Life Sciences (ACHV) Free Cash Flow (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Free Cash Flow came in at -$6.9 million in Q1 2026, up 37.48% YoY from -$5.0 million in Q1 2025, and up 61.51% on a QoQ basis from -$18.0 million in Q4 2025.
Achieve Life Sciences (ACHV) Free Cash Flow (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Free Cash Flow data on file, last reported at -$6.9 million in Q1 2026.
- Quarterly Free Cash Flow rose 37.48% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.3 million (down 27.48% YoY) and the FY2025 annual result came in at -$49.5 million, down 66.28% from the prior year.
- Free Cash Flow advanced to -$6.9 million in Q1 2026, from -$18.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$4.4 million in Q4 2023 to a low of -$18.0 million in Q4 2025.
- A 5-year average of -$8.7 million and a median of -$8.3 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 113.55% — and 2023, when it soared 60.78%.
- Tracing ACHV's Free Cash Flow over 5 years: stood at -$11.1 million in 2022, then soared by 60.78% to -$4.4 million in 2023, then tumbled by 110.27% to -$9.2 million in 2024, then plunged by 96.02% to -$18.0 million in 2025, then surged by 61.51% to -$6.9 million in 2026.
- The last three Free Cash Flow figures came in at -$6.9 million (Q1 2026), -$18.0 million (Q4 2025), and -$11.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | -10.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.78 Mn |
| Jun 30, 2026 | -10.78 Mn |
| Mar 31, 2026 | -6.93 Mn |
| Mar 31, 2026 | -6.93 Mn |
| Dec 31, 2025 | -18.01 Mn |
| Dec 31, 2025 | -18.01 Mn |
| Sep 30, 2025 | -11.29 Mn |
| Sep 30, 2025 | -11.29 Mn |
| Jun 30, 2025 | -9.11 Mn |
| Jun 30, 2025 | -9.11 Mn |
| Mar 31, 2025 | -11.09 Mn |
| Mar 31, 2025 | -11.09 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Sep 30, 2024 | -10.37 Mn |
| Sep 30, 2024 | -10.37 Mn |
| Jun 30, 2024 | -4.92 Mn |
| Jun 30, 2024 | -4.92 Mn |
| Mar 31, 2024 | -5.29 Mn |
| Mar 31, 2024 | -5.29 Mn |